NTRB: חוב כולל להון Nutriband Inc.

The price history of the separate_debt_total_eq metric for Nutriband Inc. (NTRB) is 0.04. The company's business is independent of economic cycles, as the production of patches for opioid addiction relies on FDA decisions. Revenues are based on the licensing of unique patents for transdermal substance delivery. Additionally, the enterprise minimizes environmental impact by implementing medical waste recycling and biodegradable packaging.

For Nutriband Inc. (NTRB), the balance between debt and equity determines the funding stability for aggressive R&D in transdermal drug delivery systems. By analyzing changes in the total debt-to-equity ratio, investors assess the degree of leverage within the asset structure, allowing them to differentiate genuine financial recovery from a temporary reduction in debt load amid a liquidity shortage.